Articles

• A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis

  J.M. Burton, S. Kimball, R. Vieth, A. Bar-Or, H.-M. Dosch, R. Cheung, D. Gagne, C. D'Souza, M. Ursell, P. O'Connor

  • Abstract
  • Full Text
  • Full Text (PDF)
• Rituximab add-on therapy for breakthrough relapsing multiple sclerosisA 52-week phase II trial

  R.T. Naismith, L. Piccio, J.A. Lyons, J. Lauber, N.T. Tutlam, B.J. Parks, K. Trinkaus, S.K. Song, A.H. Cross

  • Abstract
  • Full Text
  • Full Text (PDF)

  CME Course
• Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes

  N. De Stefano, A. Giorgio, M. Battaglini, M. Rovaris, M.P. Sormani, F. Barkhof, T. Korteweg, C. Enzinger, F. Fazekas, M. Calabrese, D. Dinacci, G. Tedeschi, A. Gass, X. Montalban, A. Rovira, A. Thompson, G. Comi, D.H. Miller, M. Filippi

  • Abstract
  • Full Text
  • Full Text (PDF)
• Cross-sectional study assessing long-term safety of interferon-β-1b for relapsing-remitting MS

  A.T. Reder, G.C. Ebers, A. Traboulsee, D. Li, D. Langdon, D.S. Goodin, T. Bogumil, K. Beckmann, A. Konieczny

  • Abstract
  • Full Text
  • Full Text (PDF)
• All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2

  M. Labussière, A. Idbaih, X.-W. Wang, Y. Marie, B. Boisselier, C. Falet, S. Paris, J. Laffaire, C. Carpentier, E. Crinière, F. Ducray, S. El Hallani, K. Mokhtari, K. Hoang-Xuan, J.-Y. Delattre, M. Sanson

  • Abstract
  • Full Text
  • Full Text (PDF)
• Low risk of rebound events after a short course of clopidogrel in acute TIA or minor stroke

  O.C. Geraghty, N.L.M. Paul, A. Chandratheva, P.M. Rothwell

  • Abstract
  • Full Text
  • Full Text (PDF)
• Treatment of restless legs syndrome with pregabalinA double-blind, placebo-controlled study

  D. Garcia-Borreguero, O. Larrosa, A.-M. Williams, J. Albares, M. Pascual, J.C. Palacios, C. Fernandez

  • Abstract
  • Full Text
  • Full Text (PDF)